Alport syndrome

Lore & Background

Alport syndrome is caused by an inherited defect in type IV collagen, a structural material needed for normal function of different body parts. Since type IV collagen is found in the ears, eyes, and kidneys, this explains why the syndrome affects these seemingly unrelated areas. Depending on the mutation's location in the genome, Alport syndrome can present as X-linked (XLAS), autosomal recessive (ARAS), or autosomal dominant (ADAS) forms.

Blood in urine is universal and appears from early infancy. Proteinuria develops as kidney disease progresses. Hearing loss develops progressively, usually when kidney function is normal but proteinuria is substantial; it begins with reduced ability to hear high-frequency sounds. Eye abnormalities include lenticonus, keratoconus, cataracts, and retinal flecks, though these rarely threaten vision. Diffuse leiomyomatosis of the esophagus and tracheobronchial tree has been reported in some families.

Reader's Guide

Alport syndrome is significant as a model genetic disorder illustrating how a single defective structural protein—type IV collagen—can cause dysfunction across multiple organ systems. Its identification by Cecil A. Alport in 1927 marked an early recognition of hereditary kidney disease. The syndrome's legacy includes advancing understanding of basement membrane biology and the role of collagen networks. Diagnosis relies on clinical features, family history, biopsy findings (including the characteristic 'basketweave' appearance on electron microscopy), and increasingly genetic testing. Treatment with ACE inhibitors can slow kidney function deterioration. The condition highlights the importance of genetic counseling, as inheritance patterns vary. Despite its rarity, Alport syndrome has contributed to broader knowledge of hereditary nephritis and the molecular basis of sensorineural hearing loss.

Did You Know?

• Alport syndrome was first identified in a British family by physician Cecil A. Alport in 1927.
• Blood in urine is universal in Alport syndrome and identifiable from early infancy.
• Hearing loss in Alport syndrome is not usually complete; good communication is almost always possible with hearing aids.
• Alport syndrome is caused by mutations in COL4A3, COL4A4, or COL4A5 genes, affecting type IV collagen.

The Man Behind the Name

Alport syndrome bears the surname of the British physician Cecil A. Alport, who in 1927 first recognized the condition within a single family, identifying a pattern of progressive kidney damage paired with hearing impairment that ran through multiple generations. Before his description, the cluster of symptoms lacked a unifying label. For a time, the condition was loosely grouped under the heading "hereditary nephritis," a term that proved deeply misleading because countless other inherited kidney diseases also carry that name. Alport's careful family-based observation helped separate this specific collagenopathy from the broader category of inherited renal disorders. Despite its rarity—roughly one in five to ten thousand children is affected—the syndrome has remained a distinctive entity in nephrology and genetics ever since. The name Alport attached to the condition in 1927 endures as a reminder that a single physician's meticulous attention to one family's medical history can carve out an entirely new chapter in disease classification.

A Single Protein, Three Organs

The root cause of Alport syndrome lies in a structural defect in type IV collagen, a specialized protein that forms the thin, sheet-like basement membranes supporting cells throughout the body. Specifically, mutations in any of three genes—COL4A3, COL4A4, or COL4A5—disrupt the assembly of what is called the "345" collagen network, a critical scaffold in the basement membranes of the kidney glomerulus, the inner ear, and the eye. Because this same network also appears in the alveoli of the lungs and other tissues, the damage is not confined to one organ. In the glomerulus, when the 345 network fails to form, a fetal scaffold called the "112" network, which is normally replaced during development, persists into adulthood, leaving the filtration barrier structurally compromised. This single molecular explanation elegantly accounts for why a child might present with blood in the urine, progressive hearing loss, and subtle eye changes all stemming from one inherited collagen defect.

The Clinical Tapestry

Classic Alport syndrome unfolds as a multi-system condition that typically declares itself in late childhood or young adulthood, though milder mutations or carrier status can delay onset and soften the picture. The renal story begins early: microscopic blood in the urine is essentially universal and detectable on a simple dipstick from infancy, while visible episodes of haematuria may punctuate the first years of life. As the kidneys deteriorate, protein leaks into the urine, a finding that now signals the need for ACE-inhibitor therapy, and eventually the loss of filtration capacity may necessitate dialysis or transplantation. In parallel, hearing—perfect at birth—gradually erodes, beginning with high-frequency sensorineural loss and slowly encroaching on lower frequencies, though complete deafness is uncommon and hearing aids typically preserve functional communication. The eyes contribute their own catalogue of findings: lenticonus, keratoconus, cataracts, corneal erosion, and macular flecks, most of which spare vision unless lens changes emerge later in life.

Inheritance Patterns and the Road Ahead

How Alport syndrome is passed through families depends on which collagen gene carries the mutation. In roughly eighty-five percent of cases the defect sits on the X chromosome in the COL4A5 gene, producing an X-linked pattern: males, with a single X, tend toward severe kidney failure, while females with two X chromosomes more often show persistent microscopic haematuria without progressing to end-stage disease. When both copies of COL4A3 or COL4A4 on chromosome 2 are mutated, the condition follows an autosomal recessive path, and the parents are typically unaffected carriers. Historically described autosomal dominant forms are now generally reclassified as separate entities, such as MYH9-related giant-platelet disorders. Beyond the classic triad, some families develop diffuse leiomyomatosis of the oesophagus and airways, presenting in late childhood with dysphagia, recurrent bronchitis, and stridor, confirmed by CT or MRI. A very rare overlap involving adjacent COL4A5 and COL4A6 genes can produce smooth-muscle tumours in the oesophagus or female genital tract, and isolated cases of aortic dissection have been noted in early-onset disease.

Gallery